Process for in vivo treatment of specific biological targets in bodily fluids

• US 8,507,212 B2
• Filed: 01/10/2012
• Issued: 08/13/2013
• Est. Priority Date: 03/07/2001
• Status: Expired due to Fees

• Current Assignee: Celltraffix, Inc.
• Original Assignee: Biomed Solutions, LLC
• Inventors: Connelly, Patrick R., Helfer, Jeffrey L., Custer, Andrew W., Kim, Michael B.
• Primary Examiner(s): Chin, Chris L
• Application Number:
  US13/346,932
• Publication Number:
  US 20120179143A1
• Time in Patent Office: 581 Days
• Field of Search: None
• US Class Current: 435/7.2
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002

Abstract

A process for treating biological targets in a fluid of a biological organism, including introducing a fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber for conveying a flow of the fluid, and a capture zone comprising a target-specific binding agent, wherein during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target-specific binding agent.

Claims

1. A process for treating a stem cell comprising the steps of:

introducing a fluid that includes at least one stem cell to an inlet of an assembly, the assembly comprising a flow chamber with a cross-sectional dimension less than 150 microns for conveying the fluid through the assembly, the flow chamber having a capture zone comprising a stem cell-specific binding agent;

permitting the fluid to pass through the flow chamber wherein the stem cell undergoes flux rolling along the stem cell-specific binding agent.

2. A process for treating a stem cell in the blood of an organism comprising the steps of:

placing an assembly in fluid communication with a vein or artery of an organism, the assembly comprising a flow chamber with a cross-sectional dimension less than 150 microns for conveying a first portion of blood through the assembly, the flow chamber having a capture zone comprising a stem cell-specific binding agent;

permitting blood to pass through the flow chamber, wherein during flow of the blood through the flow chamber, the stem cell undergoes flux rolling along the stem cell-specific binding agent.

3. The process as recited in claim 2, wherein the stem cell-specific binding agent is a peptide or protein.

4. The process as recited in claim 2, wherein the stem cell-specific binding agent comprises E-selectin, P-selectin, ICAM-1, cadherin-11 or a combination thereof.

5. The process as recited in claim 2, wherein the assembly further comprises a bypass chamber for conveying a second portion of blood through the assembly without passing the second portion through the flow chamber.

6. The process as recited in claim 2, wherein the assembly comprises a stent, catheter, cannula, capsule, patch, wire, infusion sleeve, fiber, shunt or graft.

7. The process as recited in claim 2, wherein the assembly is formed from a natural or synthetic polymer, fiber, diatomaceous earth, glass, metal, colloid or plastic.

8. The process as recited in claim 2, wherein the stem cell-specific binding agent is immobilized to a surface of the capture zone.

9. The process as recited in claim 2, wherein the stem cell-specific binding agent is adsorbed or covalently bonded to a surface of the capture zone.

10. The process as recited in claim 2, wherein after flux rolling of the stem cell along the stem cell-specific binding agent, the stem cell is removed from the capture zone and collected.

11. The process as recited in claim 2, wherein the flow chamber includes an access port.

12. A process for treating a cancer cell in the blood of an organism comprising the steps of:

implanting an assembly in an organism such that the assembly is in fluid communication with a vein or artery of the organism, the assembly comprising a flow chamber with a cross-sectional dimension less than 150 microns for conveying a first portion of blood through the assembly, the flow chamber having a capture zone comprising a cancer cell-specific binding agent;

permitting blood to pass through the flow chamber, wherein during flow of the blood through the flow chamber, the cancer cell undergoes flux rolling along the cancer cell-specific binding agent.

13. The process as recited in claim 12, wherein the assembly further comprises a bypass chamber for conveying a second portion of blood through the assembly without passing the second portion through the flow chamber.

14. The process as recited in claim 12, wherein the capture zone further comprises an anti-proliferative agent that is adsorbed or covalently bonded to a surface of the capture zone.

15. The process as recited in claim 12, wherein the cancer cell-specific binding agent comprises E-selectin, P-selectin, ICAM-1, cadherin-11 or a combination thereof.

16. The process as recited in claim 12, further comprising a second assembly which is substantially identical to the first assembly, the first and second assemblies being in fluid communication such that the blood passes through each assembly in series.